Access is usually developing its Cobalamin technology under multiple collaborative agreements, and is in discussion with others regarding the application of the Cobalamin technology to various other active drug candidates. While Access’ focus provides been on the oral delivery of peptides, the technology is certainly sufficiently flexible to permit us to deliver a wide range of actives, commented David P. Nowotnik, Ph.D, Gain access to’ Senior Vice President of R&D. In addition to peptide delivery, we’ve received inquiries lately about the potential of this technology to provide actives ranging from small molecules to siRNA to monoclonal antibodies. As siRNA needs to be delivered to be effective as a therapeutic intracellularly, the Cobalamin technology could be helpful as an intracellular delivery technology particularly, as the demand for supplement B12 boosts in many disease states.This is actually the first medication to inhibit mitochondria in this manner and if it proves effective in additional clinical trials, it shall start a whole new method of fighting cancer. Related StoriesFDA grants accelerated acceptance for Tagrisso to treat sufferers with advanced NSCLCCornell biomedical engineers develop 'very natural killer cells' to destroy malignancy cells in lymph nodesCrucial modification in single DNA foundation predisposes children to aggressive type of cancerMitochrondria, which are the powerhouses of the cell, are used differently by healthy cells and malignancy cells. Healthy cells make use of mitochondria as a source of energy to carry out essential functions, whereas leukemia cells use it to reproduce faster and to repair harm from chemotherapy, Pardee said.